| 股票 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▴ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 卫信康 603676 | 化学制药 | 20.5 | — | — | 2.56 | 3.6% | 60% | 53% | 20% | 0.0 | 4.0% | -7% | +10% | -12% | -27% | -37% | 28% | 40 |
| 安杰思 688581 | 医疗器械 | 19.3 | 17.0 | 1.13 | 1.62 | 2.0% | 38% | 71% | 8% | 0.3 | 3.6% | +17% | +0% | -11% | -38% | -38% | 32% | 41 |
| 普门科技 688389 | 医疗器械 | 33.8 | 22.2 | 1.01 | 2.31 | 2.5% | 36% | 63% | 22% | 1.2 | 4.0% | +2% | -11% | -12% | -21% | -34% | 26% | 48 |
| 三力制药 603439 | 中药Ⅱ | 13198.2 | — | — | 3.37 | 0.5% | 51% | 70% | 18% | 2.8 | 4.6% | +12% | -8% | +5% | -6% | -43% | 38% | 49 |
| 华特达因 000915 | 化学制药 | 14.1 | 10.5 | 1.17 | 2.27 | 9.8% | 110% | 84% | 19% | — | 8.4% | -2% | +31% | -18% | -21% | -30% | 24% | 59 |
| 康华生物 300841 | 生物制品 | 26.9 | 24.5 | 1.44 | 1.83 | 1.0% | 33% | 94% | 20% | — | 6.4% | -7% | +35% | -29% | -40% | -49% | 47% | 66 |
| 艾德生物 300685 | 医疗器械 | 19.8 | 16.2 | 1.01 | 3.53 | 2.6% | 47% | 84% | 8% | 0.4 | 4.9% | +12% | -9% | -14% | -30% | -36% | 37% | 67 |
| 欧普康视 300595 | 医疗器械 | 21.4 | 19.4 | 1.76 | 1.96 | 1.7% | 35% | 75% | 7% | 0.3 | 5.7% | +7% | -22% | -24% | -42% | -45% | 29% | 99 |
| 心脉医疗 688016 | 医疗器械 | 18.8 | 16.9 | 1.21 | 2.52 | 2.6% | 77% | 75% | 17% | 0.0 | 2.7% | +15% | -15% | -4% | -26% | -26% | 32% | 107 |
| 羚锐制药 600285 | 中药Ⅱ | 14.3 | 13.2 | 1.10 | 3.44 | 5.6% | 79% | 74% | 12% | 0.4 | 7.8% | +9% | -3% | +0% | -13% | -17% | 23% | 111 |
| 奇正藏药 002287 | 中药Ⅱ | 17.2 | — | — | 2.23 | 3.1% | 53% | 84% | 25% | 1.1 | 2.8% | +6% | +15% | -14% | -31% | -34% | 24% | 114 |
| 我武生物 300357 | 生物制品 | 27.5 | 25.8 | 1.52 | 4.17 | 1.1% | 34% | 95% | 25% | 0.0 | 3.1% | +6% | +42% | -22% | -25% | -41% | 40% | 115 |
| 西藏药业 600211 | 生物制品 | 12.5 | 12.2 | 4.07 | 3.13 | 2.3% | 60% | 94% | 10% | 1.0 | 7.1% | +5% | +22% | -9% | -14% | -36% | 36% | 123 |
| 华润江中 600750 | 中药Ⅱ | 17.0 | 15.3 | 1.39 | 3.76 | 5.9% | 96% | 65% | 29% | 0.0 | 5.0% | +3% | +8% | +5% | +12% | -19% | 28% | 149 |
| 济川药业 600566 | 中药Ⅱ | 12.9 | 13.1 | 1.64 | 1.72 | 6.7% | 76% | 82% | 14% | 0.7 | 3.4% | -12% | -3% | +5% | +4% | -18% | 29% | 237 |
| 鱼跃医疗 002223 | 医疗器械 | 23.0 | 16.7 | 1.04 | 1.94 | 4.6% | 44% | 50% | 11% | 0.0 | 5.4% | +4% | +7% | -31% | -29% | -45% | 30% | 259 |
| 新产业 300832 | 医疗器械 | 23.6 | 21.8 | 1.28 | 4.51 | 2.3% | 56% | 71% | 18% | 0.0 | 4.1% | +14% | -20% | -6% | -13% | -43% | 34% | 405 |
| 华润三九 000999 | 中药Ⅱ | 12.6 | 11.4 | 1.04 | 1.81 | 4.2% | 50% | 54% | 19% | 0.7 | 9.0% | +20% | -15% | -11% | -17% | -26% | 21% | 414 |
| 艾力斯 688578 | 化学制药 | 18.6 | 17.4 | 1.16 | 5.88 | 1.1% | 21% | 96% | 5% | 0.0 | 5.1% | +87% | +78% | +7% | +20% | -32% | 48% | 497 |
| 爱尔眼科 300015 | 医疗服务 | 30.6 | 22.1 | 1.10 | 3.39 | 2.1% | 42% | 50% | 19% | 1.1 | 4.7% | +12% | -16% | -22% | -38% | -42% | 28% | 780 |
| 迈瑞医疗 300760 | 医疗器械 | 26.2 | 23.9 | 1.71 | 5.08 | 2.5% | 65% | 64% | 18% | 0.0 | 4.4% | +3% | -24% | -10% | -30% | -45% | 28% | 2059 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。